JW Therapeutics, a Shangai, China-based clinical stage biopharmaceutical company, completed a $90m Series A financing.
The round was led by Temasek, Sequoia Capital China, and YuanMing Capital, joined by other investors including Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, and existing investors WuXi AppTec Group, and Juno Therapeutics.
Founded by Juno Therapeutics and WuXi AppTec Group in 2016, JW Therapeutics focuses on leading cell-based therapy technologies.
The company has initiated the development of its first CD19-directed investigational therapy, JWCAR029 (a CAR-T therapy being studied for the treatment of B-cell malignancies initially focusing on relapsed and refractory DCBCL). JWCAR029 has moved into clinical phase, and the IND has recently been accepted by the China Food and Drug Administration (CFDA). JW Therapeutics has built a fully validated clinical GMP facility in line with global QMS standards, and established a strong team led by seasoned biotech/pharma leaders.
Led by Hans Bishop, CEO, the company will use the funds to further advance its JWCAR029 clinical program, develop a therapeutic pipeline and build a new commercial manufacturing facility.